First human age-reversal trial underway
Sinclair's lab is conducting the first FDA-approved human clinical trial using OSK gene-therapy capsules injected into the eyes of glaucoma patients.
Where this was said
The OSK Gene Therapy and First Human Trial
At 7:57 · chapter starts 5:13
In a remarkable moment of science communication, Sinclair produces a spiked rubber ball from his pocket to illustrate the virus-like particle his lab has engineered to deliver youth-restoring genes into human eyes. The capsule, he explains, carries three genes called OSK — a modified version of Shinya Yamanaka's Nobel Prize-winning reprogramming cocktail — along with surface proteins that target it to specific tissues. The first human patient, nearly totally blind from glaucoma, received trillions of these capsules injected into his eye earlier this year, bravely volunteering to be first. Nothing has gone wrong. Sinclair explains the scientific rationale: every cell in the human body still carries an intact backup copy of its youthful programming. OSK reads and reinstalls that backup, returning 92-year-old cells to a 25-year-old state while preserving their identity — a crucial difference from the full Yamanaka reset that creates dangerous stem cells.
The First Human Age-Reversal Trial Is Happening Right Now
Sinclair's lab is running the first FDA-approved human trial to reverse aging using virus-like capsules carrying OSK genes. The first patient — nearly totally blind — received trillions of these capsules injected into his eye, and so far nothing has gone wrong.
The Backup Copy of Youth Inside Every Human Cell
Every cell in your body still carries an intact backup copy of the instructions that made you young. OSK gene therapy reads that backup and reinstalls it — turning 92-year-old cells back to their 25-year-old state without erasing their identity or causing cancer.
How Aging Reversal Was Achieved Without Creating Stem Cells
Shinya Yamanaka won the Nobel Prize for turning adult cells into stem cells using 4 genes — but stem cells have no identity and would kill you. Sinclair's team found that using only 3 of those genes (OSK, leaving out M) reverses aging 75-80% without erasing cell identity.
Similar snapshots
Ego depletion research failed to replicate
The widely cited ego-depletion model — the idea that willpower is a finite resource that gets depleted — failed to replicate in follow-up studies.
5,000–7,000 thoughts per day; recall ≈ 0
Humans are estimated to have 5,000–7,000 thoughts per day, yet can recall essentially none of them afterward, highlighting why in-the-moment emotional tracking matters.
Wandering mind = unhappy mind (Harvard study)
A large Harvard study found that a wandering mind is an unhappy mind — people report greater happiness when their attention is tethered to the present, even if the task is unpleasant.
Microplastic overestimate: gloves contaminated tests
A key study finding that we have a 'credit card's worth of plastic' in our bodies was likely skewed because researchers used nitrile gloves that shed plastic particles onto the microplastic detector.
Hyperactive amygdala + frayed PFC link
Emotionally sensitive people have a hyperactive amygdala, an underactive prefrontal cortex, and a frayed connection between the two — making emotional regulation structurally harder.
RSD visible in children as young as 2–3 years old
Rejection sensitivity can be observed as early as age 2 or 3, suggesting it has strong developmental and likely genetic roots.
Mindfulness reduces brain activation — Yale study
A Yale study found that non-judgmental observation of emotions — without rushing to resolve them — reduces activation in the brain, making it a powerful regulation tool.
Psychological immune system works strongest on irreversible decisions
Dan Gilbert's research found that the psychological immune system — the brain's ability to justify and find satisfaction in choices — activates most powerfully when a decision is perceived as irreversible.
Maximizers earn more but are less happy than satisficers
Barry Schwartz's research found that maximizers — people who try to optimize every decision — tend to achieve objectively better outcomes but report lower happiness than satisficers who choose 'good enough.'
